{"doi":"10.3390/biom15091304","title":"A Comprehensive Oncological Biomarker Framework Guiding Precision Medicine","abstract":"<jats:p>Cancer remains a major cause of mortality worldwide, driving ongoing innovation in therapeutic strategies. Immunotherapy has transformed cancer care by leveraging the immune system to target tumors, but its effectiveness is limited by tumor heterogeneity, immune resistance, and unpredictable toxicities. Moreover, the absence of robust biomarkers to predict therapeutic response and manage adverse effects remains a significant challenge. Recent advances in biomarker discovery, including liquid biopsy technologies and gut microbiota profiling, are enhancing the precision of immunotherapy and enabling more personalized cancer management. Here, we present a Comprehensive Oncological Biomarker Framework that integrates genetic and molecular testing, imaging, histopathology, multi-omics, and liquid biopsy to generate a molecular fingerprint for each patient. This holistic approach supports individualized diagnosis, prognosis, treatment selection, and response monitoring. Incorporating emerging biomarkers, such as microbiome signatures, further refines patient stratification, guiding the optimization of therapy. By uniting molecular insights with clinical and social factors, this framework aims to address tumor heterogeneity and immune evasion, ultimately improving patient outcomes through precision oncology.</jats:p>","journal":"Biomolecules","year":2025,"id":678369,"datarank":0.41588830833596724,"base_score":2.772588722239781,"endowment":2.772588722239781,"self_citation_contribution":0.41588830833596724,"citation_network_contribution":0.0,"self_endowment_contribution":0.41588830833596724,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":15,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1772439,"name":"Manpreet Sambi","orcid":null,"position":1,"is_corresponding":false},{"id":1198560,"name":"Faezeh Shekari","orcid":"0000-0001-6026-5412","position":2,"is_corresponding":false},{"id":1772440,"name":"Kosar Satari","orcid":null,"position":3,"is_corresponding":false},{"id":1772441,"name":"Roya Ghafoury","orcid":"0000-0002-1825-1284","position":4,"is_corresponding":false},{"id":1772443,"name":"Neda Ashayeri","orcid":null,"position":5,"is_corresponding":false},{"id":1223167,"name":"Paige Eversole","orcid":null,"position":6,"is_corresponding":false},{"id":377638,"name":"Narges Baluch","orcid":null,"position":7,"is_corresponding":false},{"id":1772447,"name":"William W. Harless","orcid":null,"position":8,"is_corresponding":false},{"id":621125,"name":"Lucia Anna Muscarella","orcid":"0000-0002-1866-8151","position":9,"is_corresponding":false},{"id":1182214,"name":"Herman Yeger","orcid":"0000-0002-5836-6908","position":10,"is_corresponding":false},{"id":1772450,"name":"Bikul Das","orcid":null,"position":11,"is_corresponding":false},{"id":1772451,"name":"Myron R. Szewczuk","orcid":"0000-0001-8471-5481","position":12,"is_corresponding":false},{"id":1033572,"name":"Sayan Chakraborty","orcid":"0000-0002-5591-8164","position":13,"is_corresponding":false},{"id":1772438,"name":"Reza Bayat Mokhtari","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"A Comprehensive Oncological Biomarker Framework Guiding Precision Medicine","abstract":"<jats:p>Cancer remains a major cause of mortality worldwide, driving ongoing innovation in therapeutic strategies. Immunotherapy has transformed cancer care by leveraging the immune system to target tumors, but its effectiveness is limited by tumor heterogeneity, immune resistance, and unpredictable toxicities. Moreover, the absence of robust biomarkers to predict therapeutic response and manage adverse effects remains a significant challenge. Recent advances in biomarker discovery, including liquid biopsy technologies and gut microbiota profiling, are enhancing the precision of immunotherapy and enabling more personalized cancer management. Here, we present a Comprehensive Oncological Biomarker Framework that integrates genetic and molecular testing, imaging, histopathology, multi-omics, and liquid biopsy to generate a molecular fingerprint for each patient. This holistic approach supports individualized diagnosis, prognosis, treatment selection, and response monitoring. Incorporating emerging biomarkers, such as microbiome signatures, further refines patient stratification, guiding the optimization of therapy. By uniting molecular insights with clinical and social factors, this framework aims to address tumor heterogeneity and immune evasion, ultimately improving patient outcomes through precision oncology.</jats:p>","is_dataset_classified":null,"base_score":2.772588722239781,"endowment":2.772588722239781,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"41008611","pmcid":"PMC12466961","openalex_id":"https://openalex.org/W4414091396","authors":[],"funders":[{"funder_name":"Department of Pharmacology and Therapeutics at Roswell Park Comprehensive Cancer Center","grant_id":"","title":null}],"total_grants":1,"fwci":6.9981,"citation_percentile":0.9779981,"influential_citations":0,"citation_trend":[{"year":2025,"count":3},{"year":2026,"count":12}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/2218-273X/15/9/1304/pdf?version=1757509030","host_type":"journal"},{"url":"https://www.mdpi.com/2218-273X/15/9/1304/pdf?version=1757509030","host_type":"publisher"},{"url":"https://www.mdpi.com/2218-273X/15/9/1304/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/biom15091304","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/41008611","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12466961","host_type":"repository"},{"url":"https://doaj.org/article/deb52fb159364bc389e0c08b6a1ff3e9","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12466961/","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12466961","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC12466961?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Cancer Immunotherapy and Biomarkers","Cancer Genomics and Diagnostics","Ferroptosis and cancer prognosis"],"mesh_terms":["Liquid Biopsy","Humans","Immunotherapy","Neoplasms","Biomarkers, Tumor","Precision Medicine"],"keywords":["Precision medicine","Biomarker","Immunotherapy","Personalized medicine","Liquid biopsy","Microbiome","Cancer","Biomarkers","Cancer Immunotherapy","Tumor Microenvironment","Gut Microbiome","Comprehensive Oncological Biomarker Framework"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-17T05:20:22.567848Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}